Resultado de búsqueda
Hace 2 días · UKG Workforce Central is a business app developed by Kronos Incorporated. The APK has been available since January 2011.In the last 30 days, the app was downloaded about 38 thousand times. It's highly ranked. It's rated 2.51 out of 5 stars, based on 16 thousand ratings. The last update of the app was on January 30, 2024.UKG Workforce Central has a content rating "Everyone".
Hace 4 días · Kronos Worldwide, Inc. produces and markets titanium dioxide pigments (TiO2) in Europe, North America, the Asia Pacific, and internationally. The company produces TiO2 in two crystalline forms, rutile and anatase to impart whiteness, brightness, opacity, and durability for various products, including paints, coatings, plastics, paper, fibers, and ceramics, as well as for various specialty ...
Hace 1 día · Es un sitio famoso para descargar películas gratis en 2023. Los últimos vídeos musicales, películas españolas gratis sin descargar, películas americanas, trailers, tutoriales, series y programas de televisión. Al igual que Pelis Gratis, GranTorrent se centra en las redes P2P y ofrece enlaces Bittorrent.
Hace 4 días · Últimas noticias de Películas. Mantente informado con las últimas noticias, videos y fotos de Películas que te brinda Univision
Series y películas por toDus, ¿adiós Paquete Semanal? Desde hace unos meses, el grueso de las películas y series que consume Julio Andrés Calas no viene del Paquete Semanal. Aun cuando los precios del acceso a Internet no son los más favorables, Julio descarga estos contenidos desde la red de redes, pero prácticamente gratis.
Hace 5 días · According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Kronos Bio is $4.13, with a high forecast of $6.00 and a low forecast of $2.25. The consensus rating for Kronos Bio stock is Buy based on the current 2 buy ratings for KRON. Learn more on KRON's analyst rating history.
Hace 5 días · Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors.
